Olmesartan Medoxomilo + Hidroclorotiazida Ciclum (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil combined with hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system to lower blood pressure.

• Hypertension: helps achieve target blood pressure levels in adults.
• Hypertension with fluid retention: provides additional diuretic effect to reduce edema.
• Resistant hypertension: used as part of a multi‑drug regimen when blood pressure remains uncontrolled.

• Olmesartan medoxil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis. The combined actions reduce peripheral vascular resistance and plasma volume, leading to a sustained decrease in arterial pressure.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Increased urination
• Electrolyte disturbances (e.g., low potassium)
• Mild gastrointestinal discomfort

Serious or Rare Side Effects

• Severe hypotension
• Acute kidney injury
• Hyperkalemia
• Angio‑edema
• Liver function abnormalities
• Blood cell disorders such as agranulocytosis

Before initiating therapy, consider the following safety measures:

• Renal function assessment: evaluate baseline creatinine and eGFR.
• Electrolyte monitoring: check serum potassium and sodium levels regularly.
• Pregnancy status: avoid use in confirmed or suspected pregnancy.
• Concomitant NSAID use: monitor for reduced antihypertensive effect and renal impact.
• Gout history: assess risk of increased uric acid levels.

Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan medoxil + hydrochlorothiazide can interact with several medicines.

Major Interactions (Avoid)

• Aliskiren: may cause excessive potassium loss and renal dysfunction.
• Potassium‑rich supplements: risk of hyper‑kalaemia.
• Lithium: increased lithium concentrations leading to toxicity.

Moderate Interactions (Monitor Closely)

• NSAIDs (e.g., ibuprofen): may blunt antihypertensive response and affect kidney function.
• ACE inhibitors or other ARBs: additive risk of hyper‑kalaemia and renal impairment.
• Antidiabetic drugs: may enhance glucose‑lowering effect, requiring dose adjustment.